Shares of Nektar Therapeutics up 10% on clinical results

16 June 2003 21:03  [Source: ICIS news]

HOUSTON (CNI)--Shares of drug discovery firm Nektar Therapeutics rose 10% or $1.11 to $12.59 Monday after the company said new research suggests its Exubera inhaled insulin product reduced blood sugar levels in diabetics.

Nektar Therapeutics (formerly Inhale Therapeutic Systems) said the data, based on studies by Pfizer and Aventis, was presented at the 63rd annual scientific sessions of the American Diabetes Association in New Orleans, Louisiana.

Exubera is being developed for patients with type 1 and type 2 diabetes through a collaboration between Pfizer and Aventis.

The company said there are approximately 17m in the US with diabetes with 90-95% of all cases accounting for type 2 diabetes associated with age, obesity and family history.

In type 2 diabetes, either the body does not produce enough insulin or the cells cannot properly use the insulin the body produces.

Nektar Therapeutics of San Carlos, California provides drug delivery technologies, expertise and manufacturing to enable the development of high-value, differentiated therapeutics.

By: Mike Sheridan
+1 713 525 2653

< previous article(VIDEO – ICIS news Americas Lunchtime Bulletin 18 January 2010)

For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.

Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.

Printer Friendly